Trial Profile
DOUBLE-BLIND STUDY IN PAEDIATRIC EPILEPTIC SUBJECTS AGED FROM 5 TO LESS THAN 8 YEARS TO COMPARE THE SUBJECT PREFERENCE FOR ESL SUSPENSION FORMULATION WITH ALTERNATIVE FLAVOURS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2016
Price :
$35
*
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- Sponsors Bial
- 15 Apr 2016 New trial record